Compugen Fortifies IP Portfolio: New Patent Covers Triple Anti-Cancer Combo
Wednesday, Nov 27, 2024 7:08 am ET
3min read Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, has bolstered its intellectual property portfolio with a new U.S. patent. The patent, numbered 12152084, covers the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. This patent joins Compugen's existing U.S. composition of matter patent and European and Chinese patents, strengthening its global IP strategy.
Compugen's COM902 is a reduced Fc clinical-stage antibody targeting TIGIT, which has shown promise in preclinical studies. The new patent extends the expiration date of the triple combination therapy to August 2037, providing Compugen with over 15 years of exclusive rights to this innovative approach. This patented combination holds significant market potential, as it targets multiple coinhibitory arms of the DNAM axis simultaneously, potentially enhancing antitumor immune responses. The addition of PD-1 blockade may further boost these responses, especially in tumor types refractory to PD-1 inhibition.
The patented triple combination therapy could expand immuno-oncology treatment options for patient populations non-responsive or refractory to existing immunotherapies. As the cancer immunotherapy market continues to grow, driven by advancements in checkpoint inhibitors and combination therapies, Compugen's patented triple combination therapy presents a notable opportunity.
Compugen's new U.S. patent not only strengthens its intellectual property portfolio but also impacts the competitive landscape in the immuno-oncology space. The patent's broad scope covers any anti-PD-1 and anti-PVRIG antibodies, restricting competitors' access to this specific triplet combination. Other biotech companies may need to explore alternative antibody combinations or wait for Compugen's patent to expire before developing similar therapies. After the patent expires, generic alternatives may enter the market, potentially driving down prices and expanding patient access to COM902-based therapies.
In conclusion, Compugen's new U.S. patent covering the triple combination use of COM902 with anti-PD-1 and anti-PVRIG antibodies further solidifies its position in the immuno-oncology landscape. This patented approach offers a promising new option for patients with various solid tumors, potentially expanding treatment possibilities for non-responsive or refractory patient populations. As the cancer immunotherapy market continues to grow, Compugen's strategic investment in intellectual property and innovative therapies places it well to capitalize on emerging opportunities.
Compugen's COM902 is a reduced Fc clinical-stage antibody targeting TIGIT, which has shown promise in preclinical studies. The new patent extends the expiration date of the triple combination therapy to August 2037, providing Compugen with over 15 years of exclusive rights to this innovative approach. This patented combination holds significant market potential, as it targets multiple coinhibitory arms of the DNAM axis simultaneously, potentially enhancing antitumor immune responses. The addition of PD-1 blockade may further boost these responses, especially in tumor types refractory to PD-1 inhibition.
The patented triple combination therapy could expand immuno-oncology treatment options for patient populations non-responsive or refractory to existing immunotherapies. As the cancer immunotherapy market continues to grow, driven by advancements in checkpoint inhibitors and combination therapies, Compugen's patented triple combination therapy presents a notable opportunity.
Compugen's new U.S. patent not only strengthens its intellectual property portfolio but also impacts the competitive landscape in the immuno-oncology space. The patent's broad scope covers any anti-PD-1 and anti-PVRIG antibodies, restricting competitors' access to this specific triplet combination. Other biotech companies may need to explore alternative antibody combinations or wait for Compugen's patent to expire before developing similar therapies. After the patent expires, generic alternatives may enter the market, potentially driving down prices and expanding patient access to COM902-based therapies.
In conclusion, Compugen's new U.S. patent covering the triple combination use of COM902 with anti-PD-1 and anti-PVRIG antibodies further solidifies its position in the immuno-oncology landscape. This patented approach offers a promising new option for patients with various solid tumors, potentially expanding treatment possibilities for non-responsive or refractory patient populations. As the cancer immunotherapy market continues to grow, Compugen's strategic investment in intellectual property and innovative therapies places it well to capitalize on emerging opportunities.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.